Results and long-term outcome in 39 patients with Wiskott-Aldrich syndrome transplanted from HLA-matched and -mismatched donors.
In this report, we present an analysis in 39 WAS patients treated by hematopoietic stem cell transplantation (HSCT) in our center since 1983. Fifteen patients received transplants from HLA-identical unrelated donors, 15 from nonidentical parental donors, and 9 from matched siblings. The overall survival rate is 90% in patients with matched donors and 50% in patients after nonidentical transplantation, with a mean follow-up time of 11 years. Treatment failures in the latter group were mainly related to graft rejections and to GvHD and infections following repeat transplants. Long-term survivors in both patient groups remain with few exceptions free of late complications and with stable graft function and complete donor cell chimerism. Based on our findings, we recommend early and prompt treatment of each diagnosed WAS patient if an HLA-matched, related or unrelated, donor can be identified. If this is not the case, HLA-nonidentical donor transplantation represents an alternative to be considered early in patients with severe disease.
Friedrich
Wilhelm
W
Department of Pediatrics, University of Ulm, Ulm, Germany. wilhelm.friedrich@uniklinik-ulm.de
Schütz
Catharina
C
Schulz
Ansgar
A
Benninghoff
Ulrike
U
Hönig
Manfred
M
D000998:Antiviral Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D046528:Chimerism; D000077404:Cidofovir; D016572:Cyclosporine / Q000627:therapeutic use; D003596:Cytosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006084:Graft Rejection / Q000276:immunology / Q000401:mortality / Q000628:therapy; D006086:Graft vs Host Disease / Q000276:immunology / Q000401:mortality / Q000628:therapy; D006680:HLA Antigens / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000276:immunology; D006648:Histocompatibility / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007223:Infant; D019520:Living Donors; D008297:Male; D063065:Organophosphonates / Q000627:therapeutic use; D017211:Treatment Failure; D014923:Wiskott-Aldrich Syndrome / Q000276:immunology / Q000401:mortality* / Q000601:surgery
D000998:Antiviral Agents; D006680:HLA Antigens; D007166:Immunosuppressive Agents; D063065:Organophosphonates; D016572:Cyclosporine; D003596:Cytosine; D000077404:Cidofovir